共 99 条
[1]
Park JW(2016)Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study JAMA Oncol 3 524-548
[2]
Chen M(2015)Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study Liver Int 35 2155-2166
[3]
Colombo M(2013)Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial J Natl Cancer Inst 105 59-68
[4]
Shi M(2018)Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Lancet Oncol 19 940-952
[5]
Lu LG(2017)Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Lancet 389 2492-2502
[6]
Fang WQ(2019)LBA38_PRCheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) Ann Oncol 30 874-875
[7]
Zhu AX(2009)PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV J Clin Invest 119 551-564
[8]
Finn RS(2008)PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 677-704
[9]
Edeline J(2010)PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection J Viral Hepat 17 453-458
[10]
El-Khoueiry AB(2017)Programmed cell death 1 (PD-1) and cytotoxic t lymphocyte-associated antigen 4 (CTLA-4) in viral hepatitis Int J Mol Sci 18 1517-1207